Published on 19/03/2015 by admin
Filed under Dermatology
Last modified 22/04/2025
This article have been viewed 1852 times
Jillian W. Wong Millsop and John Y.M. Koo
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports
Dermatitis artefacta is a rare, psychiatric condition in which patients self-induce a variety of skin lesions to satisfy a conscious or unconscious psychological need. However, patients will invariably deny responsibility for their injuries. The method used to inflict the lesions is typically more elaborate than simple excoriations. The appearance of the lesions depends upon the manner in which they are created, and can range from minor cuts to large areas of trauma, but is usually characterized by peculiarly shaped injured areas surrounded by normal-looking skin on parts of the body easily reachable by the dominant hand. Chemical or thermal burns, injection of foreign materials, circulatory occlusion, and tampering with old lesions, such as existing scars or prior surgical incision sites, are some common methods of self-injury. More serious wounds can result in abscesses, gangrene, or even life-threatening infection. A large proportion of patients with dermatitis artefacta manifest borderline personality disorder. Interestingly, when the patient is asked about the manner in which the skin condition evolved, he or she is often vague, generally unmoved, and cannot provide sufficient detail, an unique aspect of the illness termed the ‘hollow history.’
It is first important to rule out malingering as the etiology of the skin lesions. If the lesions were made deliberately for secondary gain, such as disability or insurance benefits, the case is no longer considered psychiatrically based, since it is then a criminal act and may eventually need to be dealt with legally. On the other hand, if the lesions are created for no material or other personal gain, then the condition is considered an illness, and medical/psychiatric intervention is warranted.
Most treatment for dermatitis artefacta is symptomatic and supportive. Protective dressings, such as an Unna boot, can occlude the involved areas and protect against further self-injurious behavior.
Antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), may be helpful for patients with dermatitis artefacta who have primary or secondary depression. If there is clinical evidence of a psychotic process, pimozide could be considered. There have also been recent case reports of patients responding to the atypical antipsychotic olanzapine when other modes of therapy, including anti-depressants and other anti-psychotics, have failed.
Importantly, physicians should be aware that patients presenting with dermatitis artefacta have a psychiatric illness, and the skin lesions are often an appeal for help. However, suggesting that the illness is psychiatrically based often has a negative effect on patient rapport. Direct confrontation should be avoided if possible, and instead, a supportive environment and a stable physician–patient therapeutic alliance should be fostered, often initially through short (so as not to ‘burn out’ the dermatologist), but frequent (so as to satisfy the patient) office visits. The clinician should be non-judgmental, empathize with the pain, discomfort, and restrictions imposed by the skin lesions, and potentially explore events and possible stressors in the patient’s life. In the case of an adolescent, the clinician should encourage the parents to become involved in identifying psychosocial stressors and helping to modify their environment to meet his or her needs. Some parents may be resistant to this diagnosis and can be angry and critical toward the clinician, so great tact is advisable. If there is a palpable antagonism (‘power struggle’) between the adolescent patient and the parents, it may be advisable to see the patient alone, without the parents, to optimize the possibility of developing therapeutic rapport with the patient. Once the patient establishes trust in the physician by means of a stable relationship, the physician may help the patient recognize the psychosocial impact of the disorder and recommend consultation with a psychiatrist or psychotherapy. This should be attempted, however, only if the clinician feels that the therapeutic rapport is strong enough to give such an intervention a likely possibility of success rather than being taken negatively and defensively by the patient.
Most patients with dermatitis artefacta have a chronic, waxing and waning course. Thus, even when the condition is under control, the physician should still follow the patient at regular intervals to ensure that the self-destructive behavior does not reinitiate. Regular visits, whether or not lesions are present, will help the patient feel cared for and diminish the need for self-mutilation as a call for help.
Rule out malingering
Rule out any organic dermatologic disease
Assess for associated psychiatric disorders, e.g., depression
Gattu S, Rashid RM, Khachemoune A. Cutis 2009; 84: 247–51.
This article is an up-to-date review of dermatitis artefacta.
Koblenzer CS. Int J Psychiatry Med 1992; 22: 47–63.
This article describes common dermatological presentations of psychopathology, including dermatitis artefacta.
Obasi OE, Naguib M. Ann Saudi Med 1999; 19: 223–7.
This is a study from Saudi Arabia of characteristics of 14 patients with dermatitis artefacta. The authors reported that 12 out of 14 were female, with a mean age of 25.9 years (range 12–71 years). Nine of the 12 females had identifiable severe emotional or psychiatric problems.
Saez-de-Ocariz M, Orozco-Covarrubias L, Mora-Magaña I, Duran-McKinster C, Tamayo-Sanchez L, Gutierrez-Castrellon P, et al. Pediatr Dermatol 2004; 21: 205–11.
In this study, the incidence of dermatitis artefacta was 1 : 23 000. It is considered rare in children; 12 of the 29 patients reported had an associated chronic illness, and seven exhibited mild mental retardation.
Finore ED, Andreoli E, Alfani S, Palermi G, Pedicelli C, Paradisi M. Pediatr Dermatol 2007; 24: E51–6.
This article is an excellent, detailed case study of a child with dermatitis artefacta that includes a thorough report of the patient’s psychodiagnostic interview.
Joe EK, Li VW, Magro CM, Arndt KA, Bowers KE. Cutis 1999; 63: 209–14.
The clinical and histopathologic features, diagnostic aids, approach to therapy and prognosis for dermatitis artefacta are discussed in this case report.
Nielsen K, Jeppesen M, Simmelsgaard L, Rasmussen M, Thestrup-Pedersen K. Acta Derm Venereol 2005; 85: 512–15.
This retrospective analysis of 57 patients reported the following findings: when self-infliction was suggested as the potential cause of illness to patients (n = 30), only one patient agreed to see a psychiatrist and two-thirds denied self-infliction or discontinued treatment. Ten patients had a psychiatric diagnosis. The most common subjective complaints were ‘pain’ (59%) and ‘itching’ (37%). The three most common lesion types were skin ulcers (72%), excoriations (46%), and erythema (30%). Of the 57 patients, 61% were treated with anxiolytic or antidepressant medications. In 32 patients, occlusive dressings were administered, and the lesions showed improvement except in two cases.
Van Moffaert M. Gen Hosp Psychiatry 1986; 8: 115–18.
Palliative dermatological measures such as occlusive bandages, ointments, or placebo drugs, as well as hospitalization that includes bathing and massaging by nurses, can have a therapeutic impact on the psychiatric problem by symbolizing the medical attention and care the patient with dermatitis artefacta is craving.
Koblenzer CS. Am J Clin Dermatol 2000; 1: 47–55.
A good review article.
Koblenzer CS. Skin Therapy Lett 2010; 15: 1–3.
This article briefly reviews treatment for dermatitis artefacta, including the use of aripiprazole.
Garnis-Jones S, Collins S, Rosenthal D. J Cutan Med Surg 2000; 4: 161–3.
Three patients successfully treated with low-dose olanzapine when multiple other therapies (including antidepressants and other antipsychotics) failed.
Gupta MA, Gupta AK. Cutis 2000; 66: 143–6.
Three patients with acne excoriée, factitious ulcers, and trichotillomania, respectively, responded to 2 to 4 weeks of olanzapine 2.5–5 mg/day.
Treatment of Skin Disease Comprehensive Therapeutic Strategies 4e
WhatsApp us